The regenerative medicine industry is estimated to be valued at USD 13385.6 million in 2023. The industry is expected to reach USD 73,084.2 million by 2033, developing at a CAGR of 18.5%.
Regenerative Medicine Industry Trend Analysis
| Attributes | Key Insights |
|---|---|
| Regenerative Medicine Industry Estimated Size in 2023 | USD 13,385.6 million |
| Projected Industry Value in 2033 | USD 73,084.2 million |
| Value-based CAGR from 2023 to 2033 | 18.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
A study by our analysts found that a 16.2% CAGR was experienced between 2017 and 2022 in the regenerative medicine industry. Global demand for regenerative medicine is predicted to increase at a CAGR of 18.5% from 2023 to 2033.
The growth of the regenerative medicine industry is directly linked to the rising prevalence of chronic diseases along with the rise in wounds and injuries in the booming population. The prevalence of diseases in the increasing population is directly linked to the growth of the regenerative medicine industry.
Several regulatory laws provide technical guidance for regenerative medicine product quality. These therapy types substantially impact health and govern the approval of regenerative medicine products.
Increased biopharma funding has contributed to the growth of the regenerative medicine industry. Multinational corporations are beginning to develop long-term business models. Increase in pet adoption, veterinary professionals are becoming interested in regenerative medicine. The demand for allogeneic stem cell therapy has increased for its safe and effective effects on animals.
| Historical CAGR from 2017 to 2022 | 16.2% |
|---|---|
| Forecast CAGR from 2023 to 2033 | 18.5% |
Principal Consultant
Forecast CAGRs from 2023 to 2033
| Australia | 11.5% |
|---|---|
| China | 27.2% |
| India | 15.5% |
| The United Kingdom | 13.2% |
The growing aging population, the adoption rate of regenerative medicines, and the prevalence of chronic diseases are contributing factors boosting the regenerative medicine industry in China. China is expected to account for a CAGR of 27.2% through 2033.
The government in China has been actively promoting the development of regenerative medicine through various initiatives and funding programs. Initiatives like the 'Made in China 2025'plan and the 'Healthy China 2030'plan prioritize the growth of biotechnology and healthcare industries, including regenerative medicine.
The demand for regenerative medicine will continue to increase in China in consideration of the above factors, promoting the value of the overall regenerative medicine Industry.
The government in Australia has been actively supporting regenerative medicine research and development through various initiatives and grants. Australian scientists, biotech companies, and biomedical engineers have been at the forefront of advancements in regenerative medicine, propelling the industry's demand. Australia is expected to expand at a CAGR of 11.5% through 2033.
The presence of a high-quality healthcare system, experienced clinical research organizations (CROs), and a regulatory framework are expected to support the market growth. Australia has a well-defined regulatory framework for regenerative medicine products, providing a clear research, development, and commercialization pathway.
India is one of the leading manufacturers of regenerative medicine. India is anticipated to rise at a CAGR of 15.5% during the forecast period due to the rising penetration of prominent manufacturers. Regenerative medicine therapies, such as stem cell-based treatments, are gaining popularity among medical tourists in the country.
The government in India has shown interest in promoting regenerative medicine and stem cell research. Initiatives such as the Department of Biotechnology's 'Stem Cell Research and Regenerative Medicine'program and the 'Make in India'campaign have provided support and incentives to the regenerative medicine industry.
The growth of the regenerative medicine industry is attributed to extensive, cutting-edge research and development being carried out in the United Kingdom. The United Kingdom is expected to expand at a CAGR of 13.2% through 2033.
Large investment allocations by both government and private players are contributing to the growth of the industry in the United Kingdom. The presence of the biotechnology and pharmaceutical industry includes established companies and startups focused on regenerative medicine in the country.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | Expected Revenue Share in 2023 |
|---|---|
| Tissue Engineering by Therapy | 43% |
| Oncology by Application | 30% |
Tissue engineering segment is expected to accumulate a market share of 43% in 2023. Tissue engineering is popular because of its adoption in tissue repair, thus accelerating Industry growth.
Tissue engineering in regenerative medicine finds applications in various medical fields, including orthopedics, cardiology, neurology, dermatology, and more. It is used for the regeneration of bone, cartilage, skin, blood vessels, and even complex organs like the heart and liver. Tissue engineering in the regenerative medicine market is highly regulated to ensure the safety and efficacy of products.
Oncology is expected to account for a value share of 40% as of 2023. The prevalence of cancer worldwide has driven this segment to be a dominant fragment, propelling sales of the overall regenerative medicine Industry.
Developing and testing regenerative medicine approaches in oncology are active areas of research and clinical trials. Regenerative medicines offer the potential to repair and regenerate these damaged tissues, improving the quality of life for cancer patients.
With several competitors in regenerative medicine, the overall industry is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as divestiture, partnerships and collaborations, and new therapy launches.
Some of the developments by players in the regenerative medicine industry are given below
| Attributes | Details |
|---|---|
| Estimated Industry Size in 2023 | USD 13385.6 million |
| Projected Industry Valuation in 2033 | USD 73084.2 million |
| Value-based CAGR 2023 to 2033 | 18.5% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | Value in USD billion |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; Middle East and Africa |
| Key Industry Segments Covered | Therapy Type, Application, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | 3M; Allergan plc; Amgen, Inc.; Aspect Biosystems; bluebird bio; Kite Pharma; Integra LifeSciences Holdings Corporation; MEDIPOST Co., Ltd.; Anterogen Co., Ltd.; MiMedx Group; Misonix, Organogenesis Inc.; Orthocell Limited; Corestem, Inc.; Spark Therapeutics; APAC Biotech; Shenzhen Sibiono; GeneTech Co., Ltd.; Smith & Nephew plc; Stryker Corporation |
The regenerative medicine industry is expected to reach USD 13385.6 million in 2023.
The market for regenerative medicine is set to expand by a CAGR of 18.5% by 2033.
The regenerative medicine industry is forecast to reach USD 73084.2 million by 2033.
A significant share of profits will likely come from the Industry in North America.
The popularity of tissue engineering is expected to grow through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Industry Analysis and Outlook 2018 to 2022 and Forecast, 2023 to 2033 5. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 5.1. Cell Therapy 5.1.1. Autologous Cell Therapy 5.1.2. Allogenic Cell Therapy 5.2. Stem Cell Therapy 5.2.1. Allogeneic Stem Cell Therapy 5.2.2. Autologous Stem Cell Therapy 5.3. Tissue-engineering 5.4. Gene Therapy 6. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Wound Care 6.2. Musculoskeletal 6.3. Oncology 6.4. Dental 6.5. DMD (Duchenne Muscular Dystrophy) 6.6. Hepatological Diseases 6.7. Inflammatory & Autoimmune Diseases 6.8. Other Therapeutic Applications 7. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033 9. Latin America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Industry Analysis and Outlook 16. Market Structure Analysis 17. Competition Analysis 17.1. 3M 17.2. Allergan plc 17.3. Amgen, Inc. 17.4. Aspect Biosystems 17.5. bluebird bio 17.6. Kite Pharma 17.7. Integra LifeSciences Holdings Corporation 17.8. MEDIPOST Co., Ltd. 17.9. Anterogen Co., Ltd. 17.10. MiMedx Group 17.11. Misonix, Organogenesis Inc. 17.12. Orthocell Limited 17.13. Corestem, Inc. 17.14. Spark Therapeutics 17.15. APAC Biotech 17.16. Shenzhen Sibiono 17.17. GeneTech Co., Ltd. 17.18. Smith & Nephew plc 17.19. Stryker Corporation 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Regenerative Medicine Market
